The ability of tolfenamic acid to penetrate the brain: A model for testing the brain disposition of candidate Alzheimer's drugs using multiple platforms

Current Alzheimer Research

Volumn 8, Issue 8, 2011, Pages 860-867

  Subaiea, Gehad M ^a   Alansi, Bothaina H ^b   Serra, David A ^a   Alwan, Maged ^c   Zawia, Nasser H ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b Sana's University   (Yemen)

^c SANA A UNIVERSITY   (Yemen)

Author keywords

Alzheimer's disease; Blood brain barrier; HPLC; Mass spectrometry; Tolfenamic acid

Indexed keywords

ATENOLOL; PROPRANOLOL; TIMOLOL; TOLFENAMIC ACID;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG PENETRATION; GUINEA PIG; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; LIQUID CHROMATOGRAPHY MASS SPECTROMETRY; MASS SPECTROMETRY; MATHEMATICAL MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ALZHEIMER DISEASE; ANIMALS; ANTHRANILIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD-BRAIN BARRIER; BRAIN; CELL MEMBRANE PERMEABILITY; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; GUINEA PIGS; MICE; MICE, INBRED C57BL;

EID: 82055197195     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720511798192691     Document Type: Article

References (27)

1. Adwan LI, Basha MR, Abdelrahim M, Subaiea GM and Zawia NH. Tolfenamic Acid Interrupts the De Novo Synthesis of the Amyloid Precursor Protein and Lowers Amyloid Beta via a Transcriptional Pathway. Curr Alzheimer Res 8(8): 860-867 (2011).
2. Urbanc B, Cruz L, Buldyrev SV, Havlin S, Irizarry MC, Stanley HE and Hyman BT. Dynamics of plaque formation in Alzheimer's disease. Biophys J 76: 1330-1334 (1999).
3. Docagne F, Gabriel C, Lebeurrier N, Lesne S, Hommet Y, Plawinski L, Mackenzie ET and Vivien D. Sp1 and Smad transcription factors co-operate to mediate TGF-beta-dependent activation of amyloid-beta precursor protein gene transcription. Biochem J 383: 393-399 (2004).
4. Christensen MA, Zhou W, Qing H, Lehman A, Philipsen S and Song W. Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1. Mol Cell Biol 24: 865-874 (2004).
5. Basha MR, Wei W, Bakheet SA, Benitez N, Siddiqi HK, Ge YW, Lahiri DK and Zawia NH. The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and beta-amyloid in the aging brain. J Neurosci 25: 823-829 (2005).
6. Abdelrahim M, Baker CH, Abbruzzese JL and Safe S. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 98: 855-868 (2006).
7. Mensch J, Oyarzabal J, Mackie C and Augustijns P. In vivo, in vitro and in silico methods for small molecule transfer across the BBB. J Pharm Sci 98: 4429-4468 (2009).
8. Arendt RM, Greenblatt DJ, deJong RH, Bonin JD and Abernethy DR. Pharmacokinetics, central nervous system uptake, and lipid solubility of propranolol, acebutolol, and sotalol. Cardiology 71: 307-314 (1984).
9. Tocco DJ, Clineschmidt BV, Duncan AE, deLuna FA and Baer JE. Uptake of the beta-adrenergic blocking agents propranolol and timolol by rodent brain: relationship to central pharmacological actions. J Cardiovasc Pharmacol 2: 133-143 (1980).
10. Di L, Kerns EH, Fan K, McConnell OJ and Carter GT. High throughput artificial membrane permeability assay for blood-brain barrier. Eur J Med Chem 38: 223-232 (2003).
11. Yoon CH, Kim SJ, Shin BS, Lee KC and Yoo SD. Rapid screening of blood-brain barrier penetration of drugs using the immobilized artificial membrane phosphatidylcholine column chromatography. J Biomol Screen 11: 13-20 (2006).
12. ACD/ChemSketch Freeware, version 12.0, Advanced Chemistry Development Inc., Toronto, ON, Canada, www.acdlabs.com, (2009).
13. C. Dollery, Therapeutic Drugs, Churchill Livingston, London, (1999).
14. ACD/ADME Suite, version 4.1, Advanced Chemistry Development Inc., Toronto, ON, Canada, www.acdlabs.com, (2009).
15. Igualada C, Moragues F and Pitarch J. Rapid method for the determination of non-steroidal anti-inflammatory drugs in animal tissue by liquid chromatography-mass spectrometry with ion-trap detector. Anal Chim Acta 586: 432-439 (2007).
16. Rishton GM, LaBonte K, Williams AJ, Kassam K and Kolovanov E. Computational approaches to the prediction of blood-brain barrier permeability: A comparative analysis of central nervous system drugs versus secretase inhibitors for Alzheimer's disease. Curr Opin Drug Discov Devel 9: 303-313 (2006).
17. Abraham MH, Takacs-Novak K and Mitchell RC. On the partition of ampholytes: application to blood-brain distribution. J Pharm Sci 86: 310-315 (1997).
18. van de Waterbeemd H, Camenisch G, Folkers G, Chretien JR and Raevsky OA. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Target 6: 151-165 (1998).
19. Hutter MC. Prediction of blood-brain barrier permeation using quantum chemically derived information. J Comput Aided Mol Des 17: 415-433 (2003).
20. Temsamani J, Scherrmann JM, Rees AR and Kaczorek M. Brain drug delivery technologies: novel approaches for transporting therapeutics. Pharm Sci Technolo Today 3: 155-62 (2000).
21. Ghose AK, Viswanadhan VN and Wendoloski JJ. A knowledgebased approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem 1: 55-68 (1999).
22. Pardridge WM. Log(BB), PS products and in silico models of drug brain penetration. Drug Discov Today 9: 392-393 (2004).
23. Reichel A and Begley DJ. Potential of immobilized artificial membranes for predicting drug penetration across the blood-brain barrier. Pharm Res 15: 1270-1274 (1998).
24. Feng MR. Assessment of blood-brain barrier penetration: in silico, in vitro and in vivo. Curr Drug Metab 3: 647-657 (2002).
25. Pardridge WM. Blood-brain barrier biology and methodology. J Neurovirol 5: 556-569 (1999).
26. Liu X, Chen C and Smith BJ. Progress in brain penetration evaluation in drug discovery and development. J Pharmacol Exp Ther 325: 349-356 (2008).
27. Pentikainen PJ, Neuvonen PJ and Backman C. Human pharmacokinetics of tolfenamic acid, a new anti-inflammatory agent. Eur J Clin Pharmacol 19: 359-365 (1981).